Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Clinical evidence: key trials and outcomes The kidney-protective potential of SGLT2 inhibitors was first identified in cardiovascular outcome trials, including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus PatientsRemoving Excess Glucose (EMPA-REG OUTCOME) [36], Canagliflozin Cardiovascular Assessment Study (CANVAS) [37], and Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARETIMI 58) [38]
Lee, MD, Healio | OSN Neurosciences Section Editor and chairman of the department of ophthalmology at Blanton Eye Institute, Houston Methodist, can be reached at [email protected]
Like semaglutide, liraglutide is contraindicated in individuals with a history of thyroid cancer or MEN 2
L-carnitine substitution in research subjects on chronic hemodialysis [PMID: 2770943] Laboratory literature summary: L-carnitine substitution in research subjects on chronic hemodialysis
IGFBP-3 (IGF Binding Protein-3) What it is: IGFBP-3 is the primary carrier protein for IGF-1 in the bloodstream
